Gujarat Magazine

Necrotizing Enterocolitis Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Noveome Biotherapeutics, Infant Bacterial Therapeutics, The Emmes Company, LLC, Siolta

 Breaking News
  • No posts were found

Necrotizing Enterocolitis Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Noveome Biotherapeutics, Infant Bacterial Therapeutics, The Emmes Company, LLC, Siolta

June 25
17:10 2024
Necrotizing Enterocolitis Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Noveome Biotherapeutics, Infant Bacterial Therapeutics, The Emmes Company, LLC, Siolta
The Necrotizing Enterocolitis market size was valued ~USD 700 million by 2034 with a significant CAGR during the study period (2020-2034).

DelveInsight’s “Necrotizing Enterocolitis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Necrotizing Enterocolitis, historical and forecasted epidemiology as well as the Necrotizing Enterocolitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Necrotizing Enterocolitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Necrotizing Enterocolitis Market Forecast

 

Some of the key facts of the Necrotizing Enterocolitis Market Report: 

  • The Necrotizing Enterocolitis market size was valued ~USD 700 million by 2034 with a significant CAGR during the study period (2020-2034)

  • In December 2023, Noveome Biotherapeutics has been granted FDA approval to advance its Phase I/II clinical trial, assessing the effectiveness of ST266 in treating necrotizing enterocolitis in premature infants.

  • In March 2023, Infinant Health revealed that it has obtained certifications from the Clean Label Project, including the “Clean Label Project” and “First 1,000 Day Promise,” for its leading product, EVIVO.

  • In 2023, the United States saw approximately 4,000 new cases of necrotizing enterocolitis, with expectations of a decrease in incidence over the forecast period.

  • Infinant Health disclosed that its flagship product, EVIVO, has secured certifications from the Clean Label Project, which include the “Clean Label Project” and the “First 1,000 Day Promise.

  • Key Necrotizing Enterocolitis Companies: Noveome Biotherapeutics, Infant Bacterial Therapeutics, The Emmes Company, LLC, Siolta Therapeutics, Ostergotland County, and others

  • Key Necrotizing Enterocolitis Therapies: ST266, IBP-9414, meropenem, STMC-106, Lactobacillus reuteri, and others

  • The Necrotizing Enterocolitis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Necrotizing Enterocolitis pipeline products will significantly revolutionize the Necrotizing Enterocolitis market dynamics.

 

Necrotizing Enterocolitis Overview

Necrotizing enterocolitis (NEC) is a serious gastrointestinal condition that primarily affects premature infants. It involves inflammation and bacterial infection of the intestine, leading to the death of intestinal tissue. NEC is considered a medical emergency due to its potential for rapid progression and severe complications.

 

Get a Free sample for the Necrotizing Enterocolitis Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/necrotizing-enterocolitis-market

 

Necrotizing Enterocolitis Epidemiology

The epidemiology section offers an in-depth look at the historical, current, and projected epidemiology trends across the seven major countries (7MM) from 2020 to 2034. By examining various studies and expert opinions, it identifies the factors driving present and future trends. This section also includes a comprehensive analysis of the diagnosed patient population and anticipated future patterns.

 

Necrotizing Enterocolitis Epidemiology Segmentation:

The Necrotizing Enterocolitis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Necrotizing Enterocolitis

  • Prevalent Cases of Necrotizing Enterocolitis by severity

  • Gender-specific Prevalence of Necrotizing Enterocolitis

  • Diagnosed Cases of Episodic and Chronic Necrotizing Enterocolitis

 

Download the report to understand which factors are driving Necrotizing Enterocolitis epidemiology trends @ Necrotizing Enterocolitis Epidemiology Forecast

 

Necrotizing Enterocolitis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Necrotizing Enterocolitis market or expected to get launched during the study period. The analysis covers Necrotizing Enterocolitis market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Necrotizing Enterocolitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Necrotizing Enterocolitis Therapies and Key Companies

  • ST266: Noveome Biotherapeutics

  • IBP-9414: Infant Bacterial Therapeutics

  • meropenem: The Emmes Company, LLC

  • STMC-106: Siolta Therapeutics

  • Lactobacillus reuteri: Ostergotland County

 

Discover more about therapies set to grab major Necrotizing Enterocolitis market share @ Necrotizing Enterocolitis Treatment Landscape

 

Necrotizing Enterocolitis Market Strengths

  • IBP-9414 represents a pharmaceutical-grade probiotic, distinguishing it from existing standard probiotics.

  • The market also benefits from research initiatives to uncover new treatment modalities and preventive measures.

 

Necrotizing Enterocolitis Market Opportunities

  • Probiotic intervention is becoming more popular due to mounting evidence of its efficiency in reducing severe NEC, lateonset sepsis, and overall infant mortality in VLBW newborns.

  • More strict regulations addressing medically beneficial probiotics that are not classifiable as drugs would be welcome.

 

Scope of the Necrotizing Enterocolitis Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Necrotizing Enterocolitis Companies: Noveome Biotherapeutics, Infant Bacterial Therapeutics, The Emmes Company, LLC, Siolta Therapeutics, Ostergotland County, and others

  • Key Necrotizing Enterocolitis Therapies: ST266, IBP-9414, meropenem, STMC-106, Lactobacillus reuteri, and others

  • Necrotizing Enterocolitis Therapeutic Assessment: Necrotizing Enterocolitis current marketed and Necrotizing Enterocolitis emerging therapies

  • Necrotizing Enterocolitis Market Dynamics: Necrotizing Enterocolitis market drivers and Necrotizing Enterocolitis market barriers 

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Necrotizing Enterocolitis Unmet Needs, KOL’s views, Analyst’s views, Necrotizing Enterocolitis Market Access and Reimbursement 

 

To know more about Necrotizing Enterocolitis companies working in the treatment market, visit @ Necrotizing Enterocolitis Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Necrotizing Enterocolitis Market Report Introduction

2. Executive Summary for Necrotizing Enterocolitis

3. SWOT analysis of Necrotizing Enterocolitis

4. Necrotizing Enterocolitis Patient Share (%) Overview at a Glance

5. Necrotizing Enterocolitis Market Overview at a Glance

6. Necrotizing Enterocolitis Disease Background and Overview

7. Necrotizing Enterocolitis Epidemiology and Patient Population

8. Country-Specific Patient Population of Necrotizing Enterocolitis 

9. Necrotizing Enterocolitis Current Treatment and Medical Practices

10. Necrotizing Enterocolitis Unmet Needs

11. Necrotizing Enterocolitis Emerging Therapies

12. Necrotizing Enterocolitis Market Outlook

13. Country-Wise Necrotizing Enterocolitis Market Analysis (2020–2034)

14. Necrotizing Enterocolitis Market Access and Reimbursement of Therapies

15. Necrotizing Enterocolitis Market Drivers

16. Necrotizing Enterocolitis Market Barriers

17.  Necrotizing Enterocolitis Appendix

18. Necrotizing Enterocolitis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

 

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Categories